National Institute of Health’s Focus on Drug Rescue to Benefit VistaGen Therapeutics (VSTA)
VistaGen Therapeutics is a 16-year-old biotechnology company that uses human pluripotent stem cell (hPSC) technology to devise a new platform for new drug development with a core focus on drug rescue. Their commercial platforms consist of bioassay systems. Essentially, bioassay refers to that portion of medical research that involves testing the biological activity of a substance by usage of a live animal (in vivo) or living human tissue or cells (in vitro). Pluripotent stem cells are undifferentiated human cells that can be artificially grown and transformed into specific cells such as liver cells, red blood cells, heart muscle cells, and…